T-CURX
W├╝rzburg
About T-CURX
T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designed to improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $20.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: t-curx.com
- Phone: +49 0 931 250 99 712
Industries & Categories
Biotechnology, Chemical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/t-curx-86004 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.